2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations

Ming Lung Yu*, Pei Jer Chen, Chia Yen Dai, Tsung Hui Hu, Chung Feng Huang, Yi Hsiang Huang, Chao Hung Hung, Chun Yen Lin, Chen Hua Liu, Chun Jen Liu, Cheng Yuan Peng, Han Chieh Lin, Jia Horng Kao, Wan Long Chuang

*此作品的通信作者

研究成果: Article同行評審

44 引文 斯高帕斯(Scopus)

摘要

Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been reported in Taiwan, especially in high-risk populations including people who inject drugs (PWID) and patients requiring dialysis. Besides, certain populations merit special considerations due to suboptimal outcome, potential drug–drug interaction, or possible side effect. Therefore, in the second part of this 2-part consensus, the Taiwan Association for the Study of the Liver (TASL) proposes the treatment recommendations for the special population in order to serve as guidance to optimizing the outcome in the direct-acting antiviral (DAA) era. Special populations include patients with acute or recent HCV infection, previous DAA failure, chronic kidney disease, decompensated cirrhosis, HCC, liver and other solid organ transplantations, receiving an HCV viremic organ, hepatitis B virus (HBV) and HCV dual infection, HCV and human immunodeficiency virus (HIV) coinfection, active tuberculosis infection, PWID, bleeding disorders and hemoglobinopathies, children and adolescents, and pregnancy. Moreover, future perspectives regarding the management of hepatitis C are also discussed and summarized in this consensus statement.

原文English
頁(從 - 到)1135-1157
頁數23
期刊Journal of the Formosan Medical Association
119
發行號7
DOIs
出版狀態Published - 7月 2020

指紋

深入研究「2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations」主題。共同形成了獨特的指紋。

引用此